Amygdala-specific AMPA receptor NAM
PTSD (with secondary indications for aggression and impulsivity)
Key Facts
About Neurovation Labs
Neurovation Labs is a private, preclinical biotech firm pioneering a targeted approach to mental health by developing region-selective drugs for CNS disorders. Its core strategy involves a proprietary drug discovery platform designed to create precision neuromodulators that act on specific brain regions, such as the amygdala, to treat conditions like PTSD while minimizing side effects. The company's lead asset is a negative allosteric modulator (NAM) of amygdala-specific AMPA receptors for PTSD, with secondary indications. Founded in 2018, Neurovation Labs is pre-revenue and is building its scientific and strategic profile through patent issuance, media engagement, and conference presentations.
View full company profile